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and vitrification of oocytes and embryos.les, no fresh embryo transfer in the stimulated cycle is advisable. The cryopreservation of zygotes and the
transfer of blastocysts in a cryo-embryo transfer is an option to circumvent an inadequate uterine environment due to risk of ovarian
hyperstimulation syndrome, inappropriate endometrium build up, endometrial polyps or uterine myomas. For this strategy, highly
secure and safe cryopreservation protocols are advisable. This study describes a protocol for aseptic vitrification of zygotes that
results in high survival rates and minimizes the potential risk of contamination in liquid nitrogen during cooling and long-term stor-
age. In mouse zygotes, there was no difference in efficiency as compared with a conventional open vitrification system. In IVF
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fresh culture. A clinical study comprising 173 cryo-cycles with a transfer of blastocysts originating from vitrified zygotes showed
an ongoing pregnancy rate of 40.9%. The live birth rate per patient was 36.8%. A combination of good clinical results and increased
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In a certain percentage of IVF cycles, no fresh embryo trans-
fer is advisable due to health risks for the patients and/or an
impaired uterine environment not providing an optimal envi-
ronment for implantation. One indication to vitrify embryos
is ovarian hyperstimulation syndrome (OHSS), which implies
– next to the medical dangers for the patient – a potentially
decreased endometrial receptivity due to histologically
advanced and genomically dysregulated endometrial tissue
as suggested by Check et al., 1999 and Shapiro et al., 2011.
Other medical situations to cancel fresh embryo transfers
are inappropriate endometrium build up, the occurrence of
endometrial polyps or uterine myomas. Using highly efficient
cryopreservation protocols is a reliable strategy to maximize
the chances of pregnancy, substituting fresh with
cryo-embryo transfer and thereby transferring the embryo
in a well-prepared luteal phase. The cryopreservation of
zygotes and the transfer of blastocysts in a cryo-embryo
transfer after extended culture to day 5 has already been
reported as a reliable strategy (Shapiro et al., 2009; Cohen
et al., 2012). Apart from these reasons, in some countries,
including, for example, Germany and Switzerland, legal
restrictions make it necessary to cryopreserve the fertilized
oocytes at the zygote stage. This is also an option for couples
with ethical concerns because it circumvents the culturing
and cryopreservation of late-stage embryos. Furthermore,
cryopreservation at the 2-pronuclei (2PN) stage can be con-
sidered a valuable tool to overcome problems of synchroni-
zation between donor and recipient in egg donation cycles.
Due to high success rates, vitrification has become the
preferred method for the cryopreservation of human
oocytes and blastocysts in IVF programmes worldwide. Sur-
prisingly, this method has not reached the same level of
popularity when it comes to the cryopreservation of human
2PN embryos. Only a handful of cases and findings have been
published (Isachenko et al., 2004, 2005; Liebermann and
Tucker, 2002; Naether et al., 2008; Park et al., 2000;
Selman and El-Danasouri, 2002) and the number of
manuscripts describing the clinical application of 2PN
vitrification remains extremely limited (Al-Hasani et al.,
2007; Kuwayama et al., 2005), even though cryopreserva-
tion is justified for a wide range of different reasons as pre-
viously stated.
One drawback of the vitrification protocols employed is
the direct contact of the embryos with liquid nitrogen (LN2)
during cooling and the persistent presence of LN2 in the vit-
rification device. The study group has, therefore, estab-
lished a protocol for aseptic hermetically closed straws
minimizing the potential risk of contact with pathogens
and reactive chemical compounds present in LN2.
Vitrification is the conversion of a liquid into a glass-like
state without the formation of crystals. It was postulated
that ultra-rapid cooling and warming rates were mandatory
during the vitrification process to reduce the risk of intra-
cellular crystal formation and the concomitant damage of
cell structures. To achieve ultra-rapid cooling rates,
embryos are placed in a very small amount of cryoprotec-
tant of less than 1 ll on open carrier devices, which are
directly plunged into LN2. Thereby, the embryos come into
direct contact with LN2, which is generally non-sterile andcontains reactive compounds. The carriers are loaded into
straws in the LN2 bath, which means that the embryos
remain in direct contact with LN2 in the straws during the
whole storage time.
Although the question of contamination by bacteria,
viruses or fungi during cooling or storage in LN2 is being
debated, the mere probability of contamination raises
safety concerns (Bielanski and Vajta, 2009; Bielanski, 2012;
Cobo et al., 2012). For this reason, great effort is taken to
at least minimize the risk of contamination for the embryos
during the vitrification process and when they are directly
plunged into LN2. Various methods for sterilizing LN2,
including ceramic filters (Cobo et al., 2011) or UV-light
simultaneously with hermetical cryostorage (Parmegiani
et al., 2010, 2011), are under development and are both
technically complex and expensive.
However, even avoiding potential contact with infectious
material at the point of vitrification, a possible cross-
contamination or other detrimental effects of LN2, i.e.
the constant exposure to toxic low-molecular-weight com-
pounds, still remain if the devices are not hermetically
closed (Yan et al., 2011). Although the probability of con-
tamination in LN2 is still being discussed, this risk is impor-
tant and indicates that the storage system, especially for
long-term storage conditions, should be revised. Contact
with LN2 in the cryovial can be avoided through either the
storage of the samples in LN2 vapour (Cobo et al., 2010)
or the use of closed embryo carrier systems. Closed loading
systems that can achieve suitable cooling and warming rates
have successfully been applied for human blastocysts, for
example (Vanderzwalmen et al., 2009, 2010).
As far as is known, no clinical data on the aseptic vitrifi-
cation of human 2PN-embryos vitrified in hermetically
closed straws on a large scale are available to date. Before
considering aseptic vitrification of human zygotes as a stan-
dard for cryopreservation our IVF centre, an aseptic vitrifi-
cation protocol in closed vitrisafe devices was first
validated on mice at the 2PN stage. To achieve this objec-
tive, the developmental potential to form blastocysts after
vitrification was compared for closed and open devices.
In patients who required the vitrification of embryos for
medical reasons, for example, OHSS or insufficient endome-
trium build up, aseptic vitrification was applied on zygotes.
The successful clinical application of the aseptic vitrification
protocol was verified by analysing survival rates, blastocyst
formation, ongoing pregnancy rates (OPR) and live birth rates
(LBR) in 173 vitrification–warming cycles. Furthermore,
during the first year of applying the vitrification of zygotes,
the efficiency of the vitrification protocol was evaluated in
a sibling analysis comparing the developmental capacity of
vitrified and non-vitrified 2PN to form blastocysts.
Materials and methods
Mice zygotes: retrieval, culture and study design
FVB/N mouse inbred strains (Charles River, France), age
5–7 weeks, were stimulated with 3.5 IU of pregnant mare’s
serum gonadotrophin (Folligon, Intervet, The Netherlands)
injected intraperitoneally, followed by an injection of 5 IU
human chorionic gonadotrophin (HCG; Chorulon; Intervet,
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mated with a male of the same strain. The mice presenting
a vaginal plug were killed on day 0.5 post coitum, enabling
the collection of the zygotes after surgical opening of the
ampulla.
Retrieved zygotes were randomly allocated to either vit-
rification in aseptic straws or in open devices. Vitrification
was performed as described below. After warming, zygotes
were kept in 50 ll drops of homemade M16 medium, cov-
ered with oil (Fertipro-Bernem-Belgium), in a humidified
5% CO2 incubator at 37.5C. The survival rate after warming
and the development of the embryos to expanded (day 5)
and fully hatched blastocysts (day 6) were evaluated.
Patients: ovarian stimulation and embryo culture
This retrospective study comprises a total of 159 patients
(aged 34.5 ± 4.2 years; range 23–42) with embryos vitrified
at the 2PN stage in aseptic vitrisafe devices between July
2007 and March 2011 (Figure 1). Embryo transfers took
place between January 2009 and September 2011. Fresh
embryo transfers were cancelled due to OHSS (117 cycles),
insufficient endometrium build up (20 cycles) and other
medical reasons (22 cycles), such as the occurrence of endo-
metrial polyps, uterine myomas or fever. Ovarian stimula-
tion was performed using the long protocol (Zech et al.,
2007). Oocyte retrieval was carried out 36 h post HCG
administration followed by culture of the oocyte–cumu-
lus–complexes in human tubal fluid medium (LifeGlobal,
Ontario, Canada) for 2–4 h. Oocytes were then fertilized
using either standard insemination, intracytoplasmic sperm
injection or intracytoplasmic morphologically selected
injection (Vanderzwalmen et al., 2008). Subsequently, theFigure 1 Stuinjected oocytes were cultured in Global medium (LifeGlob-
al) supplemented with 7.5% human serum albumin (HSA;
LifeGlobal). Fertilization was assessed 16–20 h post insem-
ination, followed by direct fresh culture to day 5 or vitrifica-
tion of the 2PN cells (Figure 1). After warming, fertilized
oocytes were cultured in four-well dishes (Nunc, Roskilde,
Denmark) or five-well dishes (MTG, Germany) in Global
medium supplemented with 7.5% HSA until day 5. On days
2 and 4, the medium was refreshed.
On day 5, the embryo quality was evaluated and blasto-
cysts were selected for embryo transfer. The blastocyst
quality was assessed according to the degree of blastocoele
expansion and the quality of both the inner cell mass and
the trophectoderm according to the classification of Gard-
ner (Gardner et al., 2000). Blastocysts with a degree of
expansion of 2, 3, 4 and 5 and with A grading for inner cell
mass and trophectoderm or a combination of A and B grad-
ing were classified as top-quality blastocysts.
Hormone replacement therapy was administered to each
group of patients prior to cryo-embryo transfer. After con-
firming steroid down-regulation, oestrogen therapy consist-
ing of increasing doses of oestradiol valerate (Progynova;
Schering) was started until the appropriate thickness of
the endometrium (>8 mm) had been achieved. From that
day on, intramuscular or intravaginal progesterone was
administered until week 16. Informed consent was signed
by all patients.
Vitrification and warming protocols
Vitrification and warming solutions
The non-vitrifying and vitrifying solutions were those
described for the vitrification of blastocysts (Vanderzwalmendy design.
594 P Vanderzwalmen et al.et al., 2009). Briefly, two non-vitrifying solutions were
prepared in phosphate-buffered saline (Fertipro, Bernem,
Belgium) or Global HEPES (LifeGlobal, Ontario, Canada)
containing 20% HSA: NVS 5/5, containing 5% (v/v) ethylene
glycol and 5% (v/v) dimethylsulphoxide; and NVS 10/10,
containing 10% (v/v) ethylene glycol and 10% (v/v) dimeth-
ylsulphoxide. The vitrification solution (VS) was composed
of 20% (v/v) ethylene glycol and 20% (v/v) dimethylsulphox-
ide, 25 lmol/l (10 mg/ml) Ficoll (70,000 MW) and 0.75 mol/l
sucrose. Warming was performed in five steps in sucrose
solution from 1 to 0.125 mol/l in PBS with 10% HSA or with
Global HEPES and 10% HSA.
Carrier devices
Vitrification in an open carrier device (mice experiment)
was carried out in hemi-straws (Astro-Med-Tec, Austria).
This previously described carrier consists of a large gutter
onto which a small quantity of cryoprotectant (<1 ll) con-
taining the zygotes is deposited. An ultra-rapid cooling rate
of >20.000C/min is achieved through the direct contact of
the biological material with LN2. The hemi-straws were sub-
sequently inserted into a larger pre-cooled 0.3 ml straw
(Cryo Bio System (CBS), France) (Vanderzwalmen et al.,
2003) and closed under LN2.
The vitrisafe plug (VitriMed, Austria), designed for the
aseptic vitrification of blastocysts, was used as a hermeti-
cally closed device (Vanderzwalmen et al., 2009). The
zygotes were placed into the vitrisafe gutter in a small
quantity of vitrification solution (<1 ll). The gutter was
inserted in the CBS straw and immediately welded before
being plunged into LN2. This ensured the hermetic isolation
of the cells from the liquid nitrogen.
Vitrification and warming procedures
All steps took place at room temperature (22–25C). Petri
dishes with 50 ll of NVS 5/5 or NVS 10/10 covered with oil
(Irvine, Santa Ana, USA) were prepared. Mice and human
2PN embryos were exposed in NVS 5/5 for 5 min and in
NVS 10/10 for 5 min 30 s. Finally, the zygotes were washed
by repeatedly pipetting in the VS before placing them into
the gutter (5–10 mice zygotes or 2–4 human zygotes per
gutter) on the open or closed carrier device. The time from
placing the cells into the VS and loading them into the gut-
ter of both carriers, followed by either plunging them
directly into LN2 or inserting them into the protective straw,
welding it and then plunging them into LN2 was 60 s.
After removing the hemi-straw or the vitrisafe, their gut-
ters containing the 2PN were instantaneously immersed in 1
mol/l sucrose solution at room temperature for warming.
After 1 min, the zygotes were transferred to 0.75, 0.5, 0.25
and 0.125 mol/l sucrose for 1, 1, 2 and 2 min respectively.
Subsequently, they were directly placed in 500 ll culture
medium for 15 min and rinsed twice before further culture.
Clinical outcomes
Sibling analysis of blastocyst development in fresh or
vitrified human zygotes
A sibling analysis compared the efficiency of the vitrification
procedure in 19 OHSS patients presenting a large number of
zygotes (Figure 1). For this purpose, the fertilized oocyteswere randomly divided into two groups: one half was asep-
tically vitrified in vitrisafe straws, whereas the other half
was kept in culture for 5 days until the blastocyst stage prior
to vitrification. When the patients presented for the first
cryo-embryo transfer, the vitrified zygotes were warmed
and cultured to day 5. In-vitro criteria for survival were
established by assessing the percentage of blastocysts com-
pared with that of the fresh control group.
Pregnancy, implantation and birth rate
The pregnancy rate among the patients who received
embryos from aseptically vitrified zygote cultures was con-
firmed by a positive test for bHCG 14 days after embryo
transfer. Clinical pregnancy was defined as the presence
of a gestational sac at 6 weeks and ongoing pregnancy was
defined as the observation of fetal heartbeat by ultrasound
8–12 weeks after embryo transfer. The implantation rate
was calculated by the number of fetal heart beats divided
by the number of embryos transferred. The results are pre-
sented in terms of delivery for the embryo transfers per-
formed in 2009 and 2010.
Statistics
Differences in the implantation rates and pregnancy rates
and live births were evaluated using Pearson’s chi-squared
test. A two-tailed t-test was used to test for differences
in blastocyst quality and growth. Differences between the
groups were considered statistically significant when the
P-value was <0.05. Statistical analysis was performed using
Statistical Package for Social Sciences version 17.0 for Win-
dows (SPSS, USA).Results
Vitrification of mouse zygotes in open and closed
carriers
After collection, mouse zygotes were randomly allocated
between the two groups. A total of 53 sibling zygotes were
vitrified in open straws allowing for direct contact with LN2,
and 52 zygotes were vitrified in hermetically closed vitrisafe
straws (Table 1). A total of five assays were performed. The
survival rate after warming was 98.1% for both groups. On
day 5, the number of blastocysts was 42 in the open straw
group (80.8%) and 34 blastocysts hatched on day 6 (81.0%).
A total of 43 blastocysts were obtained in the cultures
derived from aseptically vitrified zygotes (84.3%) and 36
blastocysts hatched on day 6 (83.7%). No statistical differ-
ence between the groups was detected.
Human blastocyst development in fresh cultures
versus cultures from aseptically vitrified zygotes
From a total of 499 collected oocytes, 348 zygotes were
obtained (Table 2). Some of the zygotes was randomly allo-
cated for direct vitrification (n = 184) whereas the others
were kept in culture until day 5 (n = 164). In the subsequent
cryo-embryo transfer cycle, the vitrified zygotes were
warmed and cultured to day 5. The blastocyst development
Table 3 Clinical pregnancies after zygote vitrification with
the vitrisafe carrier device (2009–2011; 159 patients).
Parameter Sample
Patient age (years) 34.5 ± 4.2
Warming cycles 179
Cycles with no blastocysts 6 (3.4)
Embryo transfers 173
2PN warmed 1538
2PN intact after warming 1429 (92.9)
Blastocysts 587 (41.1)
Top-quality blastocysts 272 (46.3)
Embryos transferred (n, mean per transfer) 312 (1.8)
Clinical pregnancies 78
Per embryo transfer (%) 45.1
Per patient (%) 49.1
Ongoing pregnancies 65
Per embryo transfer (%) 37.6
Per patient (%) 40.9
Implantations 76
Per embryo transferred (%) 24.4
Values are mean ± SD, n or n (%), unless otherwise stated.
Table 2 Blastocyst development of fresh versus aseptically





Patient age (years) 32.5 ± 4.2
2PN 348
2PN per culture 164 184
Survival after warming – 176 (95.7)
Blastocysts 45 (27.4) 46 (26.1)
Top-quality
blastocysts
29 (64.4) 24 (52.2)
Values are mean ± SD, n or n (%). There were no significant differ-
ences between fresh and vitrified zygotes (chi-squared test).
Table 1 Blastocyst development of mouse zygotes vitrified in





2PN vitrified 53 52
Viable after warming 52 (98.1) 51 (98.1)
Blastocysts 42 (80.8) 43 (84.3)
Fully hatched
blastocysts
34 (81.0) 36 (83.7)
Values are n or n (%). There were no significant differences between
type of straw (chi-squared test).
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sibling zygotes kept in fresh culture. Of 164 2PN in fresh cul-
ture, 45 (27.4%) developed to blastocysts on day 5 and 29
(64.4%) of these were classified as top-quality blastocysts.
In the vitrified sibling group, 176 2PN of 184 (95.7%) were
viable after warming. The developmental potential of the
vitrified zygotes to develop to blastocysts (26.1%) and
top-quality blastocysts (52.2%) showed no difference as
compared with the fresh culture. All blastocysts obtained
in the fresh cultures were subsequently cryopreserved.
Survival, blastocyst development, pregnancy and
implantation rates after vitrification of zygotes in
closed carrier devices
Of 159 patients, 1538 2PN oocytes were vitrified aseptically
and warmed for a total of 173 embryo transfers. A total of
1429 zygotes (92.9%) survived the aseptic vitrifica-
tion–warming process (Table 3). After 5 days in culture,
587 (41.1%) developed to blastocysts, of which 272 (46.3%)
showed top quality. Of the 179 warming cycles, six (3.4%)
embryo transfers had to be cancelled due to the absence
of blastocyst formation. A total of 312 embryos were trans-
ferred (mean 1.8 embryos per embryo transfer). Eight
weeks after transfer, 65 patients were tested positive for
fetal heartbeat (OPR per embryo transfer 37.6%) and a total
of 76 embryos implanted (implantation rate per embryo
transferred 24.4%).Deliveries and take-home baby rate
Between January 2009 and December 2010, 91 embryo
transfers of blastocysts from aseptically vitrified 2PN were
performed in the study institute (Table 4). Only in four
warming cycles (4.2%) was no embryo transfer performed
due to a lack of blastocyst development. In the 91 cycles,
165 blastocysts were transferred (mean 1.8 blastocysts per
embryo transfer). An OPR per embryo transfer of 40.7%
was obtained, as a result of which 32 patients (36.8%) deliv-
ered. No malformations in any of the 38 babies born were
reported. An implantation rate of 23% per embryo trans-
ferred was noted.
Outcome according to blastocyst quality
Blastocyst quality plays a crucial role in the potential to
implant. Therefore, the data were analysed in respect to
the quality of the embryos transferred (Table 5). At least
one top-quality blastocyst was transferred in 128 embryo
transfers (73.9%). In 45 embryo transfers (26.0%), only
non-top-quality blastocysts were available for transfer. In
the group of top-quality blastocysts, the OPR per embryo
transfer was 42.2%, which was significantly higher (P < 0.05)
than in the non-top-quality blastocyst group (24.4%). The
implantation rate was 27.4% in the top-quality blastocyst
group as compared with 15.4% in the non-top-quality group.
The differences were also statistically significant (P < 0.05).
Discussion
The objective of the present work was to establish a safe
vitrification method for zygotes from patients where a fresh
embryo transfer is not advisable due to different medical
indications. With this technique, high survival rates after
Table 4 Babies born after zygote vitrification in closed
cooling conditions (2009–2010; 87 patients).
Parameter Sample
Patient age (years) 33.4 ± 4.8
Warming cycles 95
Cycles with no blastocysts 4 (4.2)
Embryo transfers 91
2PN warmed 869
2PN intact after warming 8149 (3.7)
Blastocysts 3013 (7.0)
Top-quality blastocysts 1354 (4.9)
Embryos transferred (n, mean per transfer) 165 (1.8)
Clinical pregnancies 37
Per embryo transfer (%) 40.7
Per patient (%) 42.3
Live births 32
Per embryo transfer (%) 35.2
Per patient (%) 36.8
Babies born 38
Implantations 38
Per embryo transferred (%) 23.0
Values are mean ± SD, n or n (%), unless otherwise stated.
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embryo transfer were achieved. Therefore, cryopreserva-
tion can be performed with complete isolation of the biolog-
ical material from LN2 using the vitrisafe straw.
Prior to introducing the closed device for human zygotes,
this study conducted a sibling analysis of the post-warming
survival rates and blastocyst development of mouse zygotes
after vitrification in open and closed conditions. No
difference was noticed in the outcome of embryo develop-
ment. Subsequently, the efficiency of the closed device
was evaluated by comparing the developmental capacity
of vitrified and non-vitrified human zygotes in sibling
cultures to form blastocysts. No statistically significant
difference in the rate of blastocysts and top-quality blasto-
cysts was noticed between the vitrified and non-vitrified
group, suggesting no impairment of the developmental
potential due to the vitrification process.
These findings are reinforced in the clinical results, cov-
ering a period of 3 years, which show that no blastocysts
were observed in only 3.4% of 179 vitrification–warming
cycles. After warming, 92.9% of the zygotes were viable
and divided, resulting in a blastocyst rate of 41.1% and an
OPR per embryo transfer of 37.6%. The delivery rate calcu-
lated for embryo transfer in 2009 and 2010 was 35.2%, and a
delivery rate of 36.8% per patient was obtained. A total of
38 babies were born, of which six were twins and no malfor-
mations were reported. The quality of blastocysts was iden-
tified as a predictive factor for the success of the cryo-cycle
(as in fresh cycles). When at least one top-quality blastocyst
was transferred, a significantly higher OPR was found as
compared with non-top-quality blastocyst embryo transfer.
These findings correspond to earlier publications showing
the importance of embryo quality for embryo transfer
(Ebner et al., 2009).
In order to comply with European (European Parliament
and the Council of the European Union, 2004, 2006) as wellas with US Food and Drink Administration (Food and Drink
Administration, 2007, 2004, 1997) directives on tissue and
cell storage, requiring that gametes and embryos are pro-
tected from any possible contamination with pathogens dur-
ing vitrification and storage, it is mandatory to switch from
an open vitrification carrier device to a protocol that entails
complete isolation of the biological samples from LN2 during
both the cooling process as well as storage by hermetically
isolating the embryos from LN2 in the tanks. Until recently,
however, it was believed that the reduction in the cooling
rate associated with closed carriers impaired embryo viabil-
ity. Although reports of successful vitrification protocols
using closed devices are increasing, it is still widely believed
that reduced cooling conditions may profoundly impair
results. Some studies show that the vitrification of blasto-
cysts in closed carriers achieves promising IVF results in clin-
ical studies (Kuwayama et al., 2005; Vanderzwalmen et al.,
2009; Fasano et al., 2010; Stachecki et al., 2008). It may be
deduced from the present study that, despite the reduction
in cooling rates to less than 2000C/min in the carrier used
here, survival rates of more than 90% can be obtained, as
well as an embryo development comparable with fresh cul-
tures and high implantation rates.
Although no direct comparison between the results
obtained after fresh and cryo-embryo transfer after zygote
vitrification are possible – because cryopreservation was
always medically indicated in these patients – the data
clearly show that no decrease in the developmental
potential of the embryos was found between the two
groups. When transferred to a well-prepared uterine envi-
ronment, the embryos from fresh or cryopreserved cultures
had the same chance of successful implantation. The clini-
cal pregnancy and implantation rates for 2633 patients with
fresh embryo transfer in this centre during the same time
period were 44.2% and 23.3% per embryo transfer, respec-
tively, as compared with 45.1% and 24.4% in 159 patients
with embryo transfer from vitrified zygotes. No statistically
significant differences in the miscarriage and birth rates
between the groups were observed.
However, a large majority of assisted reproduction prac-
titioners continue to focus their attention on the cooling
rate and claim that an ultra-rapid cooling rate is mandatory
without being fully aware of the importance of the warming
rate. It has become obvious that the warming rate may play
a more essential role in modulating survival rates after vit-
rification than the cooling rate. Warming rates over
25,000C/min are obtained with the vitrisafe device when
the zygotes are directly plunged into at least 500 ll sucrose
solution.
A high warming rate prevents the vitreous water from
crystallizing during the warming phase (Seki and Mazur,
2008, 2009) and these authors conclude that a warming pro-
cess that is too slow is potentially lethal, as this may cause
the formation of ice crystals in lethal quantities. In fact,
during the process of warming, cells first devitrify when
they are warmed above the glass transition temperature.
If the warming rate is not high enough, the supercooled
liquid is transformed with great rapidity into small ice crys-
tals. Given appropriate time or low warming rates, the small
ice crystals are subjected to the phenomenon referred to as
(re)crystallization. This may in part explain why closed
carrier systems with their slower cooling rates can still be
Table 5 Clinical outcomes in relation to the quality of blastocysts transferred.
Quality of blastocysts transferred
Top-quality (117 patients) Non-top-quality (42 patients)
Patient age (years) 34.2 ± 4.4 34.6 ± 4.7
Embryo transfers 128 (73.9) 45 (26.0)
Embryos transferred (n, mean per transfer) 234 (1.8) 78 (1.7)
Clinical pregnanciesa 66 12
Per embryo transfer (%) 51.6 26.7
Per patient (%) 56.4 28.6
Ongoing pregnanciesb 54 11
Per embryo transfer (%) 42.2 24.4
Per patient (%) 46.2 26.2
Implantationsc 64 12
Per embryo transferred (%) 27.4 15.4
Values are mean ± SD, n or n (%), unless otherwise stated.
aChi-squared = 8.3, P < 0.01.bChi-squared = 4.5, P < 0.05.
cChi-squared = 4.5, P < 0.05.
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permit sufficiently fast warming rates.
It is well known that, for any given concentration of cry-
oprotectants, the critical warming rates are much higher
than the critical cooling rates (Fahy et al., 1987). Conse-
quently, the minimal concentration of cryoprotectants to
prevent crystallization during warming must be higher than
during cooling, and cooling and rewarming speeds must be
constant. This means that it might be easier to maintain a
vitrified state during the cooling than during the warming
process for the same concentration of cryoprotectants. If
the warming rate is reduced by using devices that separate
the drop containing the embryos, higher intracellular con-
centrations of cryoprotectants are needed in order to
reduce the likelihood of recrystallization, which may be
toxic for the further development.
This report shows that aseptic vitrification is a safe
method for clinical application, making it much easier to
prevent contamination during cryopreservation and storage.
Cobo et al., 2011 proposed filtration through ceramic filters
or UV-treated LN2 when using open straws in order to ensure
that the LN2 into which the samples are plunged fulfils
safety criteria. The theoretical risk of cross-contamination
in LN2 containers even at 196C has been widely debated
(AbdelHafez et al., 2011). It is well known from cryobanking
or the storage of cultured cells that contamination of LN2
with micro-organisms, for example, mycoplasma or Esche-
richia coli, is quite common (Bielanski, 2012). Although
the risk of cross-contamination is merely a theoretical one
and no contamination has been reported for cryopreserved
oocytes and blastocysts, cross-contamination in human
bone marrow has been reported in a case report addressing
the safety management of assisted reproduction (Hawkins
et al., 1996). Storage in LN2 vapour tanks has been proposed
to prevent cross-contamination during storage (Cobo et al.,
2010). However, even LN2 vapour is reported to be a risk
factor for pathogen transfer (Grout and Morris, 2009). Addi-
tionally, temperature variations within the vapour might
impair the viability of cryopreserved gametes and embryos.
During long storage, not only the problem of pathogen
contamination has to be taken into account but also thesubstantial problem of contagion with detrimental particles
that may appear in LN2. Reactive chemical compounds in
LN2 might induce biophysical injuries of the cryopreserved
samples. Methods to sterilize the LN2 prior to contact with
the gametes or embryos with UV light might theoretically
provoke the production of reactive compounds, leading in
turn to an increased risk of damage due to the physical
and chemical properties of irradiated LN2 when not care-
fully performed. In a nitrogen-saturated environment, it
was shown that the risk of radical formation due to UV ster-
ilization is nil (Parmegiani et al., 2011).
However, even the standard storage conditions and refill-
ing of the tanks can pose a potential hazard when oxygen
from surrounding air condenses and mixes with LN2 during
the regular opening of the nitrogen tank for routine refilling
or whenever straws are added or withdrawn. Although it is
generally assumed that thermally driven reactions do not
occur in cells at 196C, it has been reported that, in the
case of radiation of an LN2/oxygen mixture, a synthesis of
oxygen radicals resulting from ozone formation and decom-
position cannot be excluded and is even enhanced by the
catalytic effect of nitrogen. A recent publication reports
that mouse oocytes show impaired survival, fertilization
rates and embryonic development after prolonged contact
with LN2 (Yan et al., 2011). These findings are of special
interest as the biological sample in the open devices com-
monly used is constantly exposed to LN2 since the plug is
inserted into the outer straw in the LN2 bath. As a result,
not even the avoidance of cross-contamination in the tanks
by storage of straws in nitrogen vapour can sufficiently pro-
tect the samples. In view of the different theoretical and
hypothetical dangers that may be present during the cooling
process and storage, it is therefore recommended that only
a closed system can be used to guarantee aseptic storage
conditions.
In conclusion, in order to prevent gametes and embryos
from contamination with pathogens or chemical compounds
in LN2 and in order to adhere to statutory requirements,
closed vitrification devices should be used to separate the
probes from LN2 during the whole process. This study shows
that vitrification in aseptic devices is safe and does not
598 P Vanderzwalmen et al.impair embryo viability, developmental potential or the
implantation rate. The establishment of a successful aseptic
vitrification protocol might change the transfer strategy and
encourage cryo-embryo transfer in the hope of increasing
clinical pregnancy rates in those patients assessed with a
suboptimal uterine environment during the fresh cycle
(Cohen et al. 2012).References
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